APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 170 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $654 | -58.3% | 17,200 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $1,567 | +58.4% | 17,200 | +14.7% | 0.01% | +33.3% |
| Q1 2023 | $989 | +59.3% | 15,000 | +25.0% | 0.01% | +50.0% |
| Q4 2022 | $621 | -99.9% | 12,000 | +2.6% | 0.00% | -20.0% |
| Q3 2022 | $799,000 | +51.0% | 11,700 | 0.0% | 0.01% | +66.7% |
| Q2 2022 | $529,000 | -22.3% | 11,700 | -12.7% | 0.00% | -25.0% |
| Q1 2022 | $681,000 | +7.4% | 13,400 | 0.0% | 0.00% | +33.3% |
| Q4 2021 | $634,000 | +43.4% | 13,400 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $442,000 | -47.8% | 13,400 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $847,000 | +54.3% | 13,400 | +4.7% | 0.00% | +33.3% |
| Q1 2021 | $549,000 | -25.0% | 12,800 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $732,000 | +89.6% | 12,800 | 0.0% | 0.00% | +33.3% |
| Q3 2020 | $386,000 | -53.8% | 12,800 | -50.0% | 0.00% | -25.0% |
| Q2 2020 | $836,000 | – | 25,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |